A Peptide Vaccine Design Targeting KIT Mutations in Acute Myeloid Leukemia
Pharmaceuticals · 27.06.2023 · 16 (7) · 932
DOI: 10.3390/ph16070932 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 27.06.2023. Verfasst von Minji Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Human Ecology, Cornell University, Ithaca, NY 14850, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is a leading blood cancer subtype that can be caused by 27 gene mutations. Previous studies have explored potential vaccine and drug treatments against AML, but many were proven immunologically insignificant. Here, we targeted this issue and applied various clinical filters to improve immune response. KIT is an oncogenic gene that can cause AML when mutated and is predicted to be a promising vaccine target because of its immunogenic responses when activated. We designed a multi-epitope vaccine targeting mutations in the KIT oncogene using CD8+ and CD4+ epitopes. We selected the most viable vaccine epitopes based on thresholds for percentile rank, immunogenicity, antigenicity, half-life, toxicity, IFNγ release, allergenicity, and stability. The efficacy of data was observed through world and regional population coverage of our vaccine design. Then, we obtained epitopes for optimized population coverage from PCOptim-CD, a modified version of our original Java-based program code PCOptim. Using 24 mutations on the KIT gene, 12 CD8+ epitopes and 21 CD4+ epitopes were obtained. The CD8+ dataset had a 98.55% world population coverage, while the CD4+ dataset had a 65.14% world population coverage. There were five CD4+ epitopes that overlapped with the top CD8+ epitopes. Strong binding to murine MHC molecules was found in four CD8+ and six CD4+ epitopes, demonstrating the feasibility of our results in preclinical murine vaccine trials. We then created three-dimensional (3D) models to visualize epitope–MHC complexes and TCR interactions. The final candidate is a non-toxic and non-allergenic multi-epitope vaccine against KIT mutations that cause AML. Further research would involve murine trials of the vaccine candidates on tumor cells causing AML.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Human Ecology, Cornell University, Ithaca, NY 14850, USA.
- College of Humanities and Sciences, Virginia Commonwealth University, Richmond, VA 23284, USA.
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.
ORCID-Profile: Sivanesan Dakshanamurthy
Zitieren
APA
Kim, M., Savsani, K., & Dakshanamurthy, S. (2023). A Peptide Vaccine Design Targeting KIT Mutations in Acute Myeloid Leukemia. Pharmaceuticals, 16(7), 932. https://doi.org/10.3390/ph16070932
Vancouver
Kim M, Savsani K, Dakshanamurthy S. A Peptide Vaccine Design Targeting KIT Mutations in Acute Myeloid Leukemia. Pharmaceuticals. 2023;16(7):932. doi:10.3390/ph16070932
BibTeX
@article{Kim2023,
author = {Kim, Minji and Savsani, Kush and Dakshanamurthy, Sivanesan},
title = {A Peptide Vaccine Design Targeting KIT Mutations in Acute Myeloid Leukemia},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {7},
pages = {932},
doi = {10.3390/ph16070932}
}
EUVIMED